Lakeway, Texas (Date: 11-9-2023) – Vigilant Biosciences®, Inc. (“Vigilant”), an innovator and creator of solutions aimed at facilitating the early detection of oral cancer, is proud to announce the launch of its transformative product, the BeVigilant™ OraFusion™ System, in the United Kingdom.
The BeVigilant™ OraFusion™ System stands out as an innovative device in the oral cancer domain, serving as a critical tool in oral cancer detection by identifying specific salivary biomarkers and integrating intelligent software to evaluate clinical risk factors. Detecting oral cancer in its infancy, particularly during Stage 1 or Stage 2, can dramatically improve outcomes, increasing survival rates to an impressive 90%. The current survival rate for oral cancer is 50%, predominantly due to delayed detection and intervention.
Despite oral cancer often presenting early symptoms, current dental screening limitations hinder early diagnosis. Healthcare practitioners, while diligent, may find early malignancy identification challenging, occasionally defaulting to a cautious approach. Late-stage diagnoses often necessitate extensive surgery, impacting quality of life. However, technological advancements in diagnostic methods, like the BeVigilant™ OraFusion™ System, empower practitioners to enhance early detection and dramatically improve their accuracy in assessing patients.
“Our mission revolves around elevating survival outcomes in oral cancer through early detection,” expressed Bill Brodie, CEO of Vigilant Biosciences®. “The introduction of the BeVigilant™ OraFusion™ System to the UK market is a manifestation of our mission, to save lives through early detection, bringing renewed hope to those impacted by this disease.”
In its ongoing battle against oral cancer, Vigilant Biosciences® perpetuates its commitment to developing straightforward, accurate and economical solutions, empowering healthcare practitioners to transform lives through timely intervention. For additional information about Vigilant Biosciences® and its innovative products, please visit www.vigilantbiosciences.com.
Note: The BeVigilant™ OraFusion™ System is not available for sale in the U.S.
About Vigilant Biosciences®, Inc.
Vigilant Biosciences®, a trailblazer in the development of solutions designed to assist clinicians in the early detection of oral cancer, extends its BeVigilant™ product line, embodying simplicity, precision, and cost-effectiveness, thus enabling healthcare practitioners to enhance lives through expedited intervention. Dive deeper into the world of Vigilant Biosciences® at https://vigilantbiosciences.com/.
EN 
IT 
DE 
TR 
PT 
NL 
FR 
ES